Extended-release formulation of oxymorphone effective for pain relief in osteoarthritis

February 1, 2004

Article

The opioid oxymorphone (Numorphan, Endo) delivered in a new extended-release (ER) formulation significantly improves standard measures of pain and physical function in osteoarthritis (OA) patients, researchers reported at the American College of Rheumatology 67th Annual Scientific Meeting.

Related Content

FDA Approves First Biosimilar of Arthritis Med Actemra

October 2nd 2023

Article

Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.

Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA

March 22nd 2023

Article

Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.

FDA Approves Kevzara for Inflammatory Rheumatic Disease

March 1st 2023

Article

Kevzara is the first biologic to treat patients with polymyalgia rheumatica (PMR). It is also approved to treat rheumatoid arthritis.

Will the Biosimilar Amjevita Lower Costs?

February 2nd 2023

Article

The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.

First Humira Biosimilar is Now Available

January 31st 2023

Article

Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.